Get the Stockscreener App
0.6092
10.70%
0.0592
Humacyte Inc stock is traded at $0.6092, with a volume of 23.91M.
It is up +10.70% in the last 24 hours and down -13.91% over the past month.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$0.55
Open:
$0.5729
24h Volume:
23.91M
Relative Volume:
2.26
Market Cap:
$164.18M
Revenue:
$2.02M
Net Income/Loss:
$-97.59M
P/E Ratio:
-1.06
EPS:
-0.5747
Net Cash Flow:
$-102.38M
1W Performance:
-15.23%
1M Performance:
-13.91%
6M Performance:
-39.72%
1Y Performance:
-67.61%
1-Day Range:
$0.5261
$0.617
1-Week Range:
$0.5261
$0.7499
52-Week Range:
$0.5261
$2.55
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
0.6089 | 179.31M | 2.02M | -97.59M | -102.38M | -0.5747 |
VRTX
Vertex Pharmaceuticals Inc
|
507.43 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.63 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
843.20 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.26 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
346.42 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte (HUMA) Faces A Fresh Test As Its $4 Fair Value Narrative Holds - Yahoo Finance
Price to earnings forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Price to book forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Enterprise value to EBITDA forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Benchmark Lowers Humacyte (NASDAQ:HUMA) Price Target to $1.00 - MarketBeat
Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall - Yahoo Finance
Humacyte earnings missed by $0.07, revenue fell short of estimates - Investing.com Nigeria
Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In Women - Yahoo Finance
Humacyte Inc (HUMA) (Q2 2026) Earnings Call Highlights: Strong Trial Results and Strategic ... - au.finance.yahoo.com
Humacyte, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Humacyte (NASDAQ: HUMA) logs $54.4M loss and flags going concern risk - Stock Titan
HUMA Q2 FY2026 earnings call - finance.biggo.com
Humacyte (NASDAQ:HUMA) Releases Quarterly Earnings Results - MarketBeat
Humacyte stock maintained at Buy by BTIG on pipeline progress - Investing.com Canada
Humacyte Q2 Results: Sales Miss Estimate by 64%, Loss Widens - scanx.trade
Earnings call transcript: Humacyte misses Q2 2026 estimates as shares fall premarket - Investing.com Nigeria
Humacyte Inc reports results for the quarter ended June 30Earnings Summary - tradingview.com
Transcript : Humacyte, Inc., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com
HUMA: Breakthrough clinical results and commercial momentum position for growth and new launches in 2027 - TradingView
Humacyte Q2 Earnings Call Highlights - TradingView
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Humacyte, Inc. (HUMA) Q2 FY2026 earnings call transcript - Yahoo Finance
Form 8K Humacyte Inc For: 12 August By Investing.com - Investing.com South Africa
HUMACYTE ($HUMA) Releases Q2 2026 Earnings - Quiver Quantitative
Form 8K Humacyte Inc For: 12 August - Investing.com India
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Humacyte reports Q2 2026: Product revenue $0.4M, net loss $36.8M, cash $80.3M - TradingView
Humacyte Reports Breakthrough V012 Dialysis Access Results, FDA Accepts CTEV IND, and Second-Quarter 2026 Financial Results - Quiver Quantitative
Humacyte Q2 revenue rises to $0.4 million as net loss narrows - Quiver Quantitative
BRIEF-Humacyte Q2 Operating Expenses USD 27.402 Million - TradingView
Humacyte (NASDAQ:HUMA): What Could Today’s commercial adoption and manufacturing Update Reveal? - Kalkine Media
Humacyte Inc (HUMA) Q2 2026 Earnings Report Preview: What To Expect - Yahoo Finance
Humacyte Inc (HUMA) Q2 2026 Earnings Report Preview: What To Exp - GuruFocus
Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc.HUMA - Business Wire
Humacyte Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Certain Stock Options of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 10-AUG-2026. - marketscreener.com
Humacyte to Announce 2026 Second Quarter Fina - Moomoo
Humacyte to Report Second Quarter 2026 Financial Results and Host Corporate Update Webcast on August 12 - Quiver Quantitative
Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026 - marketscreener.com
Biotech company Humacyte to discuss six-month results Aug. 12 - Stock Titan
Humacyte, Inc. (HUMA): Investor Outlook on a High-Stakes Biotech with 188.90% Potential Upside - DirectorsTalk Interviews
Humacyte Q2 Results: Financial update scheduled for August 12 - scanx.trade
Humacyte, Inc. (HUMA) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
Humacyte (HUMA) Expected to Announce Earnings on Monday - MarketBeat
Humacyte, Inc. Revenue Breakdown – NASDAQ:HUMA - TradingView
Humacyte (NASDAQ:HUMA) Rating Increased to Sell at Wall Street Zen - MarketBeat
Humacyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Humacyte, Inc. (HUMA) Stock Analysis: A 205% Potential Upside In Innovative Biotechnology - directorstalkinterviews.com
Humacyte gets Nasdaq notice after shares trade below $1 bid-price minimum - Bitget
BlackRock (NYSE: BLK) discloses 1.5% beneficial stake in Humacyte (HUMA) - Stock Titan
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):